Kardigan, Inc.
Kardigan, Inc. (KARD) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in Princeton, United States and has 241 employees. The company is worth $1.22B. Revenue was $0 in fiscal 2025. It reported a net loss of $191.94M. The share price is 51.7% below its 52-week high of $27.00. 5 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Israel Englander (Millennium Management), at $5.32M. In that quarter, 2 of them opened or added to the position. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| OPKOpko Health Inc | $1.63 | — | 1.0x | 0.00% | -5.88% | $1.22B |
| SNDXSyndax Pharmaceuticals Inc | $13.57 | — | 80.3x | 0.00% | -255.93% | $1.21B |
| INNVInnovAge Holding Corp. | $8.85 | — | 5.1x | 0.00% | -0.26% | $1.21B |
| TRAXFirst Tracks Biotherapeutics, Inc. | $34.46 | — | 7.2x | 0.00% | — | $1.23B |
| GDRXGoodRx Holdings, Inc. | $3.62 | 72.4x | 1.9x | 0.00% | 2.52% | $1.23B |
| TNDMTandem Diabetes Care Inc | $17.15 | — | 9.1x | 0.00% | -48.03% | $1.19B |